Avadel Pharmaceuticals plc (NASDAQ:AVDL) headquartered in Dublin, will host a conference call for the investment community to discuss the 2Q20 financial results on 10th August 2020 at 8:30 AM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.avadel.com
Earnings Expectation
Avadel Pharmaceuticals plc developer of proprietary drug delivery technology, is expected to report second quarter earnings results, before market open, on Monday 10th August 2020. Analysts polled by Thomson Reuters anticipate second quarter loss of $ 0.1 per share. Looking ahead, the full year loss are expected at $ 0.61 per share on the revenues of $ 27.44 million.
Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland. The company primarily develops FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. It also markets three sterile injectable drugs used in the hospital setting, including Akovaz that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia; Bloxiverz, a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep, a phenylephrine hydrochloride injection indicated for the treatment of clinically important hypotension.
